News Related to Shuttled Monoclonal Antibody

Related coverage linked through entity extraction aliases.

Biotech Startups Tortugas Neuroscience and Korsana Biosciences Launch with $281 Million for Neurological Disorders

Jul 23, 2026

Tortugas Neuroscience and Korsana Biosciences emerged with significant funding to advance clinical-stage pipelines targeting neurological and neurodegenerative diseases. Tortugas raised $106 million, while Korsana secured $175 million to develop therapies for conditions including Alzheimer's, schizophrenia, and epilepsy.

Korsana Biosciences Emerges With $175M to Develop Next-Generation Alzheimer's Therapy

Feb 19, 2026

Korsana Biosciences launched from stealth with $175 million in funding to advance KRSA-028, a monoclonal antibody targeting amyloid beta plaques in Alzheimer's disease using a blood-brain barrier shuttle technology.